Compare TAYD & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TAYD | MIST |
|---|---|---|
| Founded | 1955 | 2003 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 132.1M | 163.2M |
| IPO Year | N/A | N/A |
| Metric | TAYD | MIST |
|---|---|---|
| Price | $55.26 | $2.36 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $6.33 |
| AVG Volume (30 Days) | 4.5K | ★ 5.3M |
| Earning Date | 01-02-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.72 | N/A |
| Revenue | ★ $44,593,219.00 | N/A |
| Revenue This Year | $10.81 | N/A |
| Revenue Next Year | $8.37 | N/A |
| P/E Ratio | $20.26 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $29.50 | $0.63 |
| 52 Week High | $56.49 | $3.06 |
| Indicator | TAYD | MIST |
|---|---|---|
| Relative Strength Index (RSI) | 70.03 | 46.58 |
| Support Level | $47.53 | $2.50 |
| Resistance Level | $52.00 | $2.73 |
| Average True Range (ATR) | 1.97 | 0.26 |
| MACD | 0.45 | -0.02 |
| Stochastic Oscillator | 83.01 | 48.62 |
Taylor Devices Inc is involved in the design, development, manufacture, and marketing of shock absorption, rate control, and energy storage devices for use in various types of machinery, equipment, and structures. The company's product line includes Seismic dampers, Fluidicshoks, Crane and industrial buffers, Self-adjusting shock absorbers, Liquid die springs, and Vibration Dampers. Its products are generally used to absorb, control, or mitigate the motion of masses caused by earthquakes or explosions. The company markets its products to various industries such as industrial, steel mills, buildings, bridges, aerospace, defense, and automotive industries.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).